abstract |
The present invention relates to neutralizing monoclonal antibodies against vascular endothelial growth factor (VEGF) and angiopoietin 2 (Ang-2), pharmaceutical compositions comprising said monoclonal antibodies, and therapeutic methods comprising administering said pharmaceutical compositions to a patient. About. |